Biologic therapies in inflammatory bowel disease

Practical Gastroenterology

Volumn 29, Issue 7, 2005, Pages 38-63

  Brown, Steven J ^a   Abreu, Maria T ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABT 874; ADALIMUMAB; ALICAFORSEN; ALPHA INTERFERON; BASILIXIMAB; BETA INTERFERON; CERTOLIZUMAB PEGOL; DACLIZUMAB; DEXTRO ARGINYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO ARGINYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO NORLEUCYLGLYCYL DEXTRO TYROSINAMIDE; EPIDERMAL GROWTH FACTOR; ETANERCEPT; FONTOLIZUMAB; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH HORMONE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G4; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 6 RECEPTOR; KERATINOCYTE GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MLN 02; NATALIZUMAB; ONERCEPT; PLACEBO; SEMAPIMOD; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG; VISILIZUMAB;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN PRESENTING CELL; ARTHRALGIA; BARRETT ESOPHAGUS; CELL PROLIFERATION; CHILL; DRUG INDUCED DISEASE; ENTERITIS; FEVER; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL MUCOSA; HEADACHE; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INTESTINE EPITHELIUM; LUPUS ERYTHEMATOSUS; MUCOSAL IMMUNITY; NAUSEA; PATHOGENESIS; PH MEASUREMENT; REVIEW; SERUM SICKNESS; SIDE EFFECT; T LYMPHOCYTE ACTIVATION;

EID: 23744510266     PISSN: 02774208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (139)

1. Podolsky DK. Inflammatory bowel disease. N Engl J Med, 2002; 347(6): 417-429.
2. Neurath MF, Finotto S, Glimcher LH.The role of Th1/Th2 polarization in mucosal immunity. Nat Med, 2002; 8(6); 567-573.
3. Fuss IJ, et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol, 1996; 157(3): 1261-1270.
4. Van Den Brande JM, Peppelenbosch MP, Van Deventer SJ. Treating Crohn's disease by inducing T lymphocyte apoptosis. Ann N Y Acad Sci, 2002; 973: 166-1680.
5. Iijima H, et al. Alteration of interleukin 4 production results in the inhibition of T helper type 2 cell-dominated inflammatory bowel disease in T cell receptor alpha chain-deficient mice. J Exp Med, 1999; 190(5): 607-615.
6. Heller F, et al. Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. Immunity; 2002; 17(5): 629-638.
7. Derkx B, et al. Tumour-necrosis-factor antibody treatment in Crohn's disease. Lancet, 1993; 342(8864): 173-174.
8. Knight DM, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol, 1993; 30(16): 1443-1453.
9. De Vos M. Review article: joint involvement in inflammatory bowel disease. Aliment Pharmacol Ther, 2004; 20 Suppl 4: 36-42.
10. Tan MH, et al. Improvement of Pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alpha monoclonal antibody. Arch Dermatol, 2001; 137(7): 930-933.
11. Fries W, et al. Treatment of acute uveitis associated with Crohn's disease and sacroileitis with infliximab. Am J Gastroenterol, 2002; 97(2): 499-500.
12. Miller AM, et al. Rapid response of severe refractory metastatic Crohn's disease to infliximab. J Gastroenterol Hepatol, 2001; 16(8): 940-942.
13. van Dullemen HM, et al. Treatment of Crohn's disease with antitumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology, 1995; 109(1): 129-135.
14. Targan SR, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med, 1997; 337(15): 1029-1035.
15. Present DH, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med, 1999; 340(18): 1398-1405.
16. Sands BE, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med, 2004; 350(9): 876-885.
17. Hanauer SB, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet, 2002; 359(9317): 1541-1549.
18. Date RS, Panesar KJ, Neilly P. Infliximab as a therapy for non-Crohn's enterocutaneous fistulae. Int J Colorectal Dis, 2004; 19(6): 603-606.
19. Rutgeerts P, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology, 2004; 126(2): 402-413.
20. Khanna D, McMahon M, Furst DE. Safety of tumour necrosis factor-alpha antagonists. Drug Saf, 2004; 27(5): 307-324.
21. Ellerin T, Rubin RH, Weinblatt ME. Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum, 2003; 48(11); 3013-3022.
22. Hamilton CD. Infectious complications of treatment with biologic agents. Curr Opin Rheumatol, 2004; 16(4): 393-398.
23. Colombel JF, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology, 2004; 126(1): 19-31.
24. Andus T, et al. Suspected cases of severe side effects after infliximab (Remicade) in Germany. Med Klin (Munich), 2003; 98(8): 429-436.
25. Cheifetz A, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol, 2003; 98(6):1315-1324.
26. Baert F, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med, 2003; 348(7): 601-608.
27. Farrell RJ, et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology, 2003; 124(4): 917-924.
28. Vermeire S, et al. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease. Am J Gastroenterol, 2002; 97(9): 2357-2363.
29. Parsi MA, et al. Predictors of response to infliximab in patients with Crohn's disease. Gastroenterology, 2002; 123(3): 707-713.
30. Fefferman DS, et al. Smoking and immunomodulators do not influence the response or duration of response to infliximab in Crohn's disease. Inflamm Bowel Dis, 2004; 10(4): 346-351.
31. Louis E, et al. A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scand J Gastroenterol, 2002; 37(7): 818-824.
32. Taylor KD, et al. ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease. Gastroenterology, 2001; 120(6): 1347-1355.
33. Esters N, et al. Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease. Am J Gastroenterol, 2002; 97(6): 1458-1462.
34. Martinez-Borra J, et al. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease. Am J Gastroenterol, 2002; 97(9): 2350-2356.
35. Pierik M, et al. Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab. Aliment Pharmacol Ther, 2004; 20(3): 303-310.
36. Vermeire S, et al. NOD2/CARD15 does not influence response to infliximab in Crohn's disease. Gastroenterology, 2002; 123(1):106-111.
37. Louis E, et al. Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease. Aliment Pharmacol Ther, 2004; 19(5): 511-519.
38. van Deventer SJ. Transmembrane TNF-alpha, induction of apoptosis, and the efficacy of TNF-targeting therapies in Crohn's disease. Gastroenterology, 2001; 121(5): 1242-1246.
39. Scallon BJ, et al. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine, 1995; 7(3): 251-259.
40. Lugering A, et al. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology, 2001; 121(5): 1145-1157.
41. ten Hove T, et al. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut, 2002; 50(2): 206-211.
42. Di Sabatino A, et al. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease. Gut, 2004; 53(1): 70-77.
43. Waetzig GH, Schreiber S. Mechanisms of infliximab: the reverse side of a drug effect. Inflamm Bowel Dis, 2004; 10 Suppl 1: S38-S43.
44. Moreland LW, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med, 1997; 337(3): 141-147.
45. Sandborn WJ, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology, 2001; 121(5): 1088-1094.
46. Van den Brande JM, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology, 2003; 124(7): 1774-1785.
47. Stephens S, et al. Comprehensive pharmacokinetics of a humanized antibody and analysis of residual anti-idiotypic responses. Immunology, 1995; 85(4): 668-674.
48. Stack WA, et al. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease. Lancet, 1997; 349(9051): 521-524.
49. Sandborn WJ, et al. An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology, 2001; 120(6): 1330-1338.
50. Sandborn WJ, et al. CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial. Gut, 2004; 53(10): 1485-1493.
51. Choy EH, et al. Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. Rheumatology (Oxford), 2002; 41(10); 1133-1137.
52. Schreiber S, et al. CDP870, a Humanized Anti-TNF Antibody Fragment, Induces Clinical Respopnse With Remission in Patients With Active Crohn's Disease. Gastroenterology, 2003; 125(2): 606-607.
53. Lorenz HM. Technology evaluation: adalimumab, Abbott laboratories. Curr Opin Mol Ther, 2002; 4(2): 185-190.
54. Sandborn WJ, Faubion WA. Biologics in inflammatory bowel disease: how much progress have we made? Gut, 2004; 53(9): 1366-1373.
55. Weinblatt ME, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum, 2003; 48(1): 35-45.
56. Hanauer S, et al. A Randomized, Double-blind, Placbo-Controlled Trial of the Human Anti-TNF-a monoclonal Antibody Adalimumab for the Induction of Remission in Patients with Moderate to Severely Active Crohn's Disease. Gastroenterology, 2004; 127(1): 332.
57. Youdim A, et al. A pilot study of adalimumab in infliximab-allergic patients. Inflamm Bowel Dis, 2004; 10(4): 333-338.
58. Sandborn WJ, et al. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol, 2004, 99(10): 1984-1989.
59. Papadakis KA, et al. Safety and Efficacy of Adalimumab (D2E7) in Crohn's Disease Patients with an Attenuated Response to Infliximab. Am J Gastroenterol, 2005; 100: 1-5.
60. Vermeire S, et al. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology, 2003; 125(1): 32-39.
61. Mohler KM, et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol, 1993; 151(3): 1548-1561.
62. Rutgeerts P, et al. Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open-label, pilot study. Aliment Pharmacol Ther, 2003; 17(2): 185-192.
63. Rutgeerts P, et al. Preliminary results of a phase i/II study of Huzaf, an anti-IFNgamma monoclonal antibody, in patients with moderate to severe active Crohn's disease [abstract]. 2002; 122: A61.
64. Hommes D, et al. Fontolizumab (Huzaf), a Humanized Anti-IFN-Gamma Antibody, Has Clinical Activity and Excellent Tolerability in Moderate to Severe Crohn's Disease. Gastroenterology, 2004; 127(1): 332.
65. Becker C, et al. Constitutive p40 promoter activation and IL-23 production in the terminal ileum mediated by dendritic cells. J Clin Invest, 2003; 112(5): 693-706.
66. Cua DJ, et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature, 2003; 421(6924): 744-748.
67. Brown SJ, et al. Altered immune system glycosylation causes colitis in alpha 1,2-fucosyltransferase transgenic mice. Inflamm Bowel Dis, 2004; 10(5): 546-556.
68. Davidson NJ, et al. IL-12, but not IFN-gamma, plays a major role in sustaining the chronic phase of colitis in IL-10-deficient mice. J Immunol, 1998; 161(6): 3143-3149.
69. Neurath MF, et al. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med, 1995; 182(5): 1281-1290.
70. Fuss IJ, et al. Anti-interleukin 12 treatment regulates apoptosis of Thl T cells in experimental colitis in mice. Gastroenterology, 1999; 117(5): 1078-1088.
71. Mannon PJ, et al. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med, 2004; 351(20): 2069-2079.
72. Gross V, et al. Evidence for continuous stimulation of interleukin-6 production in Crohn's disease. Gastroenterology, 1992; 102(2): 514-519.
73. Yamamoto M, et al. IL-6 is required for the development of Th1 cell-mediated murine colitis. J Immunol, 2000; 164(9): 4878-4882.
74. Atreya R, et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn's disease and experimental colitis in vivo. Nat Med, 2000; 6(5): 583-588.
75. Ito H, et al. Effective treatment of active Crohn's disease humanized monoclonal antibody MRA to interleukin-6 receptor: a randomized placebo-controlled trial [abstract]. Gastroenterology, 2003; 124: A25.
76. Kuhn R, et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell, 1993; 75(2): 263-274.
77. Berg DJ, et al. Enterocolitis and colon cancer in interleukin-10- deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J Clin Invest, 1996; 98(4): 1010-1020.
78. Steidler L, et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science, 2000; 289(5483): 1352-1355.
79. Nakase H, et al. New cytokine delivery system using gelatin microspheres containing interleukin-10 for experimental inflammatory bowel disease. J Pharmacol Exp Ther, 2002; 301(1): 59-65.
80. Lindsay JO, et al. Local delivery of adenoviral vectors encoding murine interleukin IO induces colonic interleukin 10 production and is therapeutic for murine colitis. Gut, 2003; 52(7): 981-987.
81. Ribbons KA, et al. Anti-inflammatory properties of interleukin-10 administration in hapten-induced colitis. Eur J Pharmacol, 1997; 323(2-3): 245-254.
82. Powrie F, et al. Regulatory interactions between CD45RBhigh and CD45RBlow CD4+ T cells are important for the balance between protective and pathogenic cell-mediated immunity. J Exp Med, 1994; 179(2): 589-600.
83. Schreiber S, et al. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology, 2000; 119(6): 1461-1472.
84. Fedorak RN, et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology, 2000; 119(6): 1473-1482.
85. Colombel JF, et al. Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease. Gut, 2001; 49(1): 42-46.
86. Trepicchio WL, et al. Recombinant human IL-11 attenuates the inflammatory response through down-regulation of proinflammatory cytokine release and nitric oxide production. J Immunol, 1996; 157(8): 3627-3634.
87. Orazi A, et al. Interleukin-11 prevents apoptosis and accelerates recovery of small intestinal mucosa in mice treated with combined chemotherapy and radiation. Lab Invest, 1996; 75(1): 33-42.
88. Ropeleski MJ, et al. Interleukin-11-induced heat shock protein 25 confers intestinal epithelial-specific cytoprotection from oxidant stress. Gastroenterology, 2003; 124(5): 1358-1368.
89. Sands BE, et al. Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease. Gastroenterology, 1999; 117(1): 58-64.
90. Sands BE, et al. Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease. Aliment Pharmacol Ther, 2002; 16(3): 399-406.
91. Cole MS, et al. HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitro. Transplantation, 1999; 68(4): 563-571.
92. Carpenter PA, et al. Non-Fc receptor-binding humanized anti-CD3 antibodies induce apoptosis of activated human T cells. J Immunol, 2000; 165(11): 6205-6213.
93. Tsao T, et al. Visilizumab, a Humanized non-FcR Binding, Anti-CD3 Monoclonal Antibody, Induces Th2 Cytokine Bias in Human Peripheral Blood Mononuclear Cells. Gastroenterology, 2004; 126(4 Supp2): A158.
94. Plevy S, et al. A Humanized Anti-CD3 Monoclonal Antibody, Visilizumab, for Treatment of Severe Steroid-Refractory Ulcerative Colitis: Results of a Phase I Study. Gastroenterology. 2004; 126(4 Supp2): A75.
95. Carpenter PA, et al. A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. Blood, 2002; 99(8): 2712-2719.
96. Malek TR, Bayer AL. Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol, 2004; 4(9): 665-674.
97. Van Assche G, et al. A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis. Am J Gastroenterol, 2003; 98(2): 369-376.
98. Creed TJ, et al. Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis. Aliment Pharmacol Ther, 2003; 18(1): 65-75.
99. Mittelbrunn M, et al. VLA-4 integrin concentrates at the peripheral supramolecular activation complex of the immune synapse and drives T helper 1 responses. Proc Natl Acad Sci USA, 2004; 101(30): 11058-11063.
100. Gordon FH, et al. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. Gastroenterology, 2001; 121(2): 268-2674.
101. Gordon FH, et al. A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin. Aliment Pharmacol Ther, 2002; 16(4): 699-705.
102. Ghosh S, et al. Natalizumab for active Crohn's disease. N Engl J Med, 2003; 348(1): 24-32.
103. Sandborn WJ, et al. Efficacy Assessment of Natalizumab in Patients with Crohn's Disease and Prior History of Anti-TNF Therapy: Results from ENACT-1. Gastroenterology, 2004; 126(4 Supp2); A76.
104. Sandborn WJ, et al. A Phase III, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Antegren (Natalizumab) in Maintaining Clinical Response and Remission in Crohn's Disease (ENACT-2). Gastroenterology, 2004; 127: 332.
105. Feagan B. et al. A Randomized Trial of a Humanized alpha4-beta7 Anitbody in Ulcerative Colitis. Gastroenterology, 2003; 125(2): 606.
106. Feagan B, et al. Efficacy and Safety of a Humanized alpha4-beta7 Antibody in Active Crohn's Disease. Gastroenterology, 2003; 2003(124): A25.
107. Bennett CF, et al. Inhibition of endothelial cell adhesion molecule expression with antisense oligonucleotides. J Immunol, 1994: 152(7): 3530-3540.
108. van Assche G, Rutgeerts P. Antiadhesion molecule therapy in inflammatory bowel disease. Inflamm Bowel Dis, 2002; 8(4): 291-300.
109. Lebedeva T, et al. Major histocompatibility complex class I-intercellular adhesion molecule-1 association on the surface of target cells: implications for antigen presentation to cytotoxic T lymphocytes. Immunology, 2004; 113(4): 460-471.
110. Yacyshyn BR, et al. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology, 1998; 114(6): 1133-1142.
111. Schreiber S, et al. Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease. Gastroenterology, 2001; 120(6): 1339-1346.
112. Yacyshyn BR, et al. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease. Gut, 2002; 51(1): 30-36.
113. Miner P, et al. An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis. Aliment Pharmacol Ther, 2004; 19(3): 281-286.
114. Procaccino F, et al. Protective effect of epidermal growth factor in an experimental model of colitis in rats. Gastroenterology, 1994; 107(1): 12-17.
115. Zeeh JM, et al. Keratinocyte growth factor ameliorates mucosal injury in an experimental model of colitis in rats. Gastroenterology, 1996; 110(4): 1077-1083.
116. Vandenbroucke K, et al. Active delivery of trefoil factors by genetically modified Lactococcus lactis prevents and heals acute colitis in mice. Gastroenterology, 2004; 127(2): 502-513.
117. Kara E, et al. The effect of recombinant human growth hormone (rhGH) on trinitrobenzene sulfonic acid-induced colitis in rats: an experimental study. Inflamm Bowel Dis, 2004; 10(2): 112-115.
118. Sinha A, et al. Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. N Engl J Med, 2003; 349(4): 350-357.
119. Sung C, et al. Pharmacologic and pharmacokinetic profile of repifermin (KGF-2) in monkeys and comparative pharmacokinetics in humans. AAPS Pharm Sci, 2002; 4(2): E8.
120. Sandborn WJ, et al. Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Aliment Pharmacol Ther, 2003; 17(11): 1355-1364.
121. Williams KL, et al. Enhanced survival and mucosal repair after dextran sodium sulfate-induced colitis in transgenic mice that overexpress growth hormone. Gastroenterology, 2001; 120(4): 925-937.
122. Slonim AE, et al. A preliminary study of growth hormone therapy for Crohn's disease. N Engl J Med, 2000; 342(22): 1633-1637.
123. Su C, et al. A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease. Gastroenterology, 2004; 126(5): 1257-1269.
124. Melis D, et al. Crohn's-like ileo-colitis in patients affected by glycogen storage disease Ib: two years' follow-up of patients with a wide spectrum of gastrointestinal signs. Acta Paediatr, 2003; 92(12): 1415-1421.
125. Hommes DW, et al. Efficacy of recombinant granulocyte colony-stimulating factor (rhG-CSF) in experimental colitis. Clin Exp Immunol, 1996; 106(3): 529-533.
126. Vaughan D, Drumm B. Treatment of fistulas with granulocyte colony-stimulating factor in a patient with Crohn's disease. N Engl J Med, 1999; 340(3): 239-240.
127. Dieckgraefe BK, Korzenik JR. Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colony-stimulating factor. Lancet, 2002; 360(9344): 1478-1480.
128. Dejaco C, et al. An open-label pilot study of granulocyte colony-stimulating factor for the treatment of severe endoscopic postoperative recurrence in Crohn's disease. Digestion, 2003; 68(2-3): 63-70.
129. Davidsen B, et al. Tolerability of interferon alpha-2b, a possible new treatment of active Crohn's disease. Aliment Pharmacol Ther, 1995; 9(1): 75-79.
130. Gasche C, et al. Prospective evaluation of interferon-alpha in treatment of chronic active Crohn's disease. Dig Dis Sci, 1995; 40(4): 800-804.
131. Madsen SM, et al. An open-labeled, randomized study comparing systemic interferon-alpha-2A and prednisolone enemas in the treatment of left-sided ulcerative colitis. Am J Gastroenterol, 2001; 96(6): 1807-1815.
132. Sumer N, Palabiyikoglu M. Induction of remission by interferon-alpha in patients with chronic active ulcerative colitis. Eur J Gastroenterol Hepatol, 1995; 7(7): 597-602.
133. Tilg H, et al. A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. Gut, 2003; 52(12): 1728-1733.
134. Salh B, et al. Curcumin attenuates DNB-induced murine colitis. Am J Physiol Gastrointest Liver Physiol, 2003; 285(1): G235-G243.
135. Hollenbach E, et al. Inhibition of p38 MAP kinase- and RICK/NF-kappaB-signaling suppresses inflammatory bowel disease. Faseb J, 2004; 18(13): 1550-1552.
136. ten Hove T, et al. Dichotomal role of inhibition of p38 MAPK with SB 203580 in experimental colitis. Gut, 2002; 50(4): 507-512.
137. Hommes D, et al. Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology, 2002; 122(1): 7-14.
138. Travis S, Yap L, Hawkey C. RDP-58: novel and effective therapy for ulcerative colitis: results of a parallel, prospective, placebo-controlled trial [abstract]. Am J Gastroenterol, 2003; 98: S239.
139. Zhao J, et al. Oral RDP58 allows CPT-11 dose intensification for enhanced tumor response by decreasing gastrointestinal toxicity. Clin Cancer Res, 2004; 10(8): 2851-2859.